scholarly journals DYSLIPIDEMIA: OVERVIEW OF THE ESC/EAS 2019 RECOMMENDATIONS FOR DIAGNOSTICS AND TREATMENT. PART 1 – RISK ASSESSMENT

2021 ◽  
Vol 19 (1) ◽  
pp. 119-122
Author(s):  
V. M. Pyrochkin ◽  
◽  
Y. I. Karpovich ◽  
E. V. Mironchik ◽  
A. V. Kovtun ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Cardiovascular Risk ◽  
European Society ◽  
Clinical Use ◽  
European Congress ◽  
European Atherosclerosis Society ◽  
Individual Assessment ◽  
High Incidence ◽  
European Society Of Cardiology

The high incidence of cardiovascular disease leads to a routine individual assessment of the patient's cardiovascular risk, and to the correction of therapy. In 2019, at the European Congress of Cardiology, updated recommendations of the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society) on the diagnosis and treatment of dyslipidemia were presented, new approaches to cardiovascular risk assessing and correction of dyslipidemia were formulated. The article discusses the main aspects of clinical use of the new recommendations for the treatment of this pathology.

scholarly journals DYSLIPIDEMIA: OVERVIEW OF THE ESC/EAS 2019 RECOMMENDATIONS FOR DIAGNOSTICS AND TREATMENT. PART 2 – TARGET THERAPY

2021 ◽  
Vol 19 (2) ◽  
pp. 236-241
Author(s):  
V. M. Pyrochkin ◽  
◽  
Y. I. Karpovich ◽  
E. V. Mironchik ◽  
A. V. Kovtun ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Clinical Application ◽  
European Society ◽  
Target Therapy ◽  
European Congress ◽  
European Atherosclerosis Society ◽  
Individual Assessment ◽  
High Incidence ◽  
European Society Of Cardiology

The high incidence of cardiovascular disease leads to a routine individual assessment of the patient's cardiovascular risk, and to the correction of the therapy. In 2019, at the European Congress of Cardiology, updated recommendations of the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society) on the diagnosis and treatment of dyslipidemia were presented, new approaches to cardiovascular risk assessing and correction of dyslipidemia were formulated. The article discusses the main aspects of clinical application of the new recommendations for the treatment of this pathology.

Cardiovascular disease prevention guidelines

ESC CardioMed ◽  
2018 ◽  
pp. 2834-2836
Author(s):  
Janet Wei
Keyword(s):  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Cardiovascular Risk ◽  
American Heart Association ◽  
Cardiovascular Prevention ◽  
Heart Association ◽  
Prevention Guidelines ◽  
European Society Of Cardiology ◽  
Cholesterol Management ◽  
Prevention Of Cardiovascular Disease

Cardiovascular prevention guidelines recommend systemic cardiovascular risk assessment in women, recognizing that women have a high lifetime risk of cardiovascular disease. While there are differences in the approach to risk assessment, both the American Heart Association and the European Society of Cardiology recommend estimation of a 10-year risk of cardiovascular disease. This chapter discusses the guidelines for aspirin use, cholesterol management, and lifestyle factors for prevention of cardiovascular disease.

scholarly journals Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study

2018 ◽  
Vol 25 (17) ◽  
pp. 1887-1898 ◽  
Author(s):  
Marcio S Bittencourt ◽  
Ron Blankstein ◽  
Michael J Blaha ◽  
Veit Sandfort ◽  
Arthur S Agatston ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Cardiovascular Mortality ◽  
European Society ◽  
Coronary Artery Calcium ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
European Society Of Cardiology

Aims The European Society of Cardiology (ESC) guideline on cardiovascular risk assessment considers coronary artery calcium a class B indication for risk assessment. We evaluated the degree to which coronary artery calcium can change the recommendation for individuals based on a change in estimated risk. Methods and results We stratified 5602 MESA participants according to the ESC recommendation as: no lipid-lowering treatment recommended ( N = 2228), consider lipid-lowering treatment if uncontrolled ( N = 1686), or lipid-lowering treatment recommended ( N = 1688). We evaluated the ability of coronary artery calcium to reclassify cardiovascular risk. Among the selected sample, 54% had coronary artery calcium of zero, 25% had coronary artery calcium of 1–100 and 21% had coronary artery calcium greater than 100. In the lipid-lowering treatment recommended group 31% had coronary artery calcium of zero, while in the lipid-lowering treatment if uncontrolled group about 50% had coronary artery calcium of zero. The cardiovascular mortality rate was 1.7%/10 years in the lipid-lowering treatment if uncontrolled, and 7.0%/10 years in the lipid-lowering treatment recommended group. The absence of coronary artery calcium was associated with 1.4%/10 years in the lipid-lowering treatment if uncontrolled group and 3.0%/10 years in the lipid-lowering treatment recommended group. Compared with coronary artery calcium of zero, any coronary artery calcium was associated with significantly higher cardiovascular mortality in the lipid-lowering treatment recommended group (9.0%/10 years), whereas only coronary artery calcium greater than 100 was significantly associated with a higher cardiovascular mortality in the lipid-lowering treatment if uncontrolled group (3.2%/10 years). Conclusion The absence of coronary artery calcium is associated with a low incidence of cardiovascular mortality or coronary heart disease events even in individuals in whom lipid-lowering therapy is recommended. A significant proportion of individuals deemed to be candidates for lipid-lowering therapy might be reclassified to a lower risk group with the use of coronary artery calcium.

scholarly journals Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries

2020 ◽  
pp. 204748732090869 ◽  
Author(s):  
Kornelia Kotseva ◽  
Guy De Backer ◽  
Dirk De Bacquer ◽  
Lars Rydén ◽  
Arno Hoes ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Primary Care ◽  
Cardiovascular Risk ◽  
Primary Prevention ◽  
European Society ◽  
Research Programme ◽  
European Countries ◽  
High Cardiovascular Risk ◽  
European Society Of Cardiology

Background European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) V in primary care was carried out by the European Society of Cardiology EURObservational Research Programme in 2016–2018. The main objective was to determine whether the 2016 Joint European Societies’ guidelines on cardiovascular disease prevention in people at high cardiovascular risk have been implemented in clinical practice. Methods The method used was a cross-sectional survey in 78 centres from 16 European countries. Patients without a history of atherosclerotic cardiovascular disease either started on blood pressure and/or lipid and/or glucose lowering treatments were identified and interviewed ≥ 6 months after the start of medication. Results A total of 3562 medical records were reviewed and 2759 patients (57.6% women; mean age 59.0 ± 11.6 years) interviewed (interview rate 70.0%). The risk factor control was poor with 18.1% of patients being smokers, 43.5% obese (body mass index ≥30 kg/m2) and 63.8% centrally obese (waist circumference ≥88 cm for women, ≥102 cm for men). Of patients on blood pressure lowering medication 47.0% reached the target of <140/90 mm Hg (<140/85 mm Hg in people with diabetes). Among treated dyslipidaemic patients only 46.9% attained low density lipoprotein-cholesterol target of <2.6 mmol/l. Among people treated for type 2 diabetes mellitus, 65.2% achieved the HbA1c target of <7.0%. Conclusion The primary care arm of the EUROASPIRE V survey revealed that large proportions of people at high cardiovascular disease risk have unhealthy lifestyles and inadequate control of blood pressure, lipids and diabetes. Thus, the potential to reduce the risk of future cardiovascular disease throughout Europe by improved preventive cardiology programmes is substantial.

Comparison of SCORE and Reynolds cardiovascular risk assessments in a cohort without cardiovascular disease

2013 ◽  
Vol 154 (43) ◽  
pp. 1709-1712 ◽  
Author(s):  
Csaba Móczár
Keyword(s):  
Cardiovascular Disease ◽  
Risk Assessment ◽  
Cardiovascular Risk ◽  
Screening Program ◽  
Risk Group ◽  
Scoring Systems ◽  
High Risk Group ◽  
Risk Assessments ◽  
Gender And Age ◽  
Medium Risk

Introduction: Cardiovascular risk assessment may help in the identification of symptom-free subjects with high cardiovascular risk. Aim: The author studied the correlation between SCORE and Reynolds risk assessment systems based on data from the cardiovascular risk screening program carried out in subjects without cardiovascular disease. Method: Data obtained from 4462 subjects (1977 men and 2485 women; mean age, 47,4 years) were analysed. The comparison was based on risk categories of the SCORE system. Results: There was a strong correlation between the two scoring systems in the low risk population (under <2% SCORE risk the Spearman rho = 1, p < 0.001). A weak correlation was found in the medium risk group (between 3–4% the Spearman rho = 0.59–0.49, p < 0.001 and between 10–14% the Spearman rho = 0.42, ns.) and a stronger correlation in the high risk group (>15% the Spearmen rho = 0.8, p = 0.017). When correlations were analysed in gender and age categories, the weakest correlation was detected in medium risk women over 40 years of age. In cases when the differences between the two scoring systems were significant, the hsCRP levels were significantly higher (4.1 vs. 5.67 mg/L, p < 0.001). Conclusions: Introduction of hsCRP into cardiovascular risk assessments can refine the risk status of symptom-free subjects, especially among intermediate risk middle-age women (two-step risk assessment). Orv. Hetil., 154 (43), 1709–1712.

NT-PROBNP AND THE CUT-OFF VALUE IN CARDIOVASCULAR DISEASES

2011 ◽  
pp. 5-12
Author(s):  
Anh Tien Hoang ◽  
Van Minh Huynh ◽  
Khanh Hoang ◽  
Huu Dang Tran ◽  
Viet An Tran
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Pilot Study ◽  
Cardiovascular Diseases ◽  
Clinical Application ◽  
European Society ◽  
The Other ◽  
Cardiac Marker ◽  
Cardiac Biomarker ◽  
European Society Of Cardiology

NT-ProBNP is a high value cardiac biomarker and widely applies in many cardiovascular diseases. The evaluation of concentration of NT-ProBNP needs the concern about age, gender, obesity and especially we need each cut-off point for each cause of cardiovascular disease in evaluation and clinical application. Because NT-ProBNP is a new cardiac marker and has been researched in 5 recent years, the cut-off of NT-ProBNP is still being studied for the clinical application in cardiovascular diseases. Only the cut-off of NT-ProBNP in diagnosis heart failure was guided by European Society of Cardiology. The meaning of introduce cut-off value of value plays an role as pilot study for the other relate study and brings the NT-ProBNP closely approach to clinical application.

Sign in / Sign up

Export Citation Format

Share Document